Nivolumab plus relatlimab induces sturdy responses in complicated melanoma
The combo of nivolumab (nivolumab) and relatlimab (Opdualag) has demonstrated scientific get advantages with a manageable protection profile in sufferers with complicated melanoma, without reference to PD-L1 and LAG-3 expression, prior PD- Have advanced on L1 or PD-1 inhibitors. In line with the findings of the continuing Section 1/2a RELATIVITY-020 trial (NCT01968109).1 Amongst evaluable sufferers … Read more